W
William Borkowsky
Researcher at New York University
Publications - 215
Citations - 10325
William Borkowsky is an academic researcher from New York University. The author has contributed to research in topics: Viral load & Vaccination. The author has an hindex of 51, co-authored 214 publications receiving 9992 citations. Previous affiliations of William Borkowsky include Cornell University & State University of New York Upstate Medical University.
Papers
More filters
Journal ArticleDOI
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.
Richard A. Koup,Jeffrey T. Safrit,Yunzhen Cao,C. A. Andrews,G. Mcleod,William Borkowsky,C. Farthing,David D. Ho +7 more
TL;DR: It is suggested that cellular immunity is involved in the initial control of virus replication in primary HIV-1 infection and a role for CTL in protective immunity to HIV- 1 in vivo is indicated.
Journal ArticleDOI
Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy.
Linqi Zhang,Sharon R Lewin,Martin Markowitz,Hsi-Hsun Lin,Eva Skulsky,Rose Karanicolas,Yuxian He,Xia Jin,Sarah Tuttleton,Mika Vesanen,Hans M. L. Spiegel,Rhonda G. Kost,Jan van Lunzen,Hans-Juergen Stellbrink,Steven M. Wolinsky,William Borkowsky,Paul Palumbo,Leondios G. Kostrikis,David D. Ho +18 more
TL;DR: Overall, it is difficult to invoke thymic regenerative failure as a generalized mechanism for CD4 lymphocyte depletion in HIV-1 infection, as α1 circle numbers are normal in a substantial subset of HIV–1–infected individuals.
Journal ArticleDOI
Live Attenuated Varicella Vaccine: Efficacy for Children With Leukemia in Remission
Anne A. Gershon,Sharon Steinberg,Lawrence D. Gelb,George J. Galasso,William Borkowsky,Philip LaRussa,Angelo Ferrara +6 more
TL;DR: Varicella vaccine was approximately 80% effective in preventing clinical varicella in children with leukemia and completely effective in protecting against severe varICElla in this high-risk group of children.
Journal ArticleDOI
A Multicenter Trial of Oral Zidovudine in Children with Advanced Human Immunodeficiency Virus Disease
Ross E. McKinney,Mary Maha,Edward M. Connor,Judith Feinberg,Gwendolyn B. Scott,Michael Wulfsohn,Kenneth McIntosh,William Borkowsky,John F. Modlin,Peggy Weintrub,Karen O'Donnell,Richard D. Gelber,Gail Knowlton Rogers,Sandra Nusinoff Lehrman,Catherine M. Wilfert +14 more
TL;DR: Zidovudine in a dose of 180 mg per square meter every six hours can be safely administered to children with advanced HIV disease, and there was marked improvement in weight gain, cognitive function, serum and cerebrospinal fluid concentrations of p24 antigen, and the proportion of cerebro Spinal fluid cultures negative for HIV.
Journal ArticleDOI
Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection.
Aimee El Hed,Alka Khaitan,Lina Kozhaya,Nicolas Manel,Demetre Daskalakis,William Borkowsky,Fred T. Valentine,Dan R. Littman,Derya Unutmaz +8 more
TL;DR: A complex perturbation of Th17 subsets during the course of HIV disease potentially through both direct viral infection and virus indirect mechanisms, such as immune activation are suggested.